Compare AbbVie Inc (ABBV) vs iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs iShares iBoxx $ Inv Grade Corporate Bond ETF — how do they compare? AbbVie Inc trades at $253.69 (market cap $449.91B), while iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $107.56. The key difference: AbbVie Inc pays a 2.72% dividend while iShares iBoxx $ Inv Grade Corporate Bond ETF pays none, and AbbVie Inc is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | LQD | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | — |
52-Week High | $261.07 | $112.91 |
52-Week Low | $184.85 | $107.12 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
LQD, the iShares iBoxx $ Investment Grade Corporate Bond ETF, is trading at $108.67, showing minimal daily change. The technical outlook is bearish based on moving averages, though short-term oscillators like the RSI suggest potential oversold conditions. Recent news highlights strong investor flows into bond ETFs amid market uncertainty and rate hike speculation, positioning LQD as a core vehicle for investment-grade corporate bond exposure.
The outlook for LQD is tied to interest rate expectations and corporate credit health. The primary opportunity lies in its role as a liquid, diversified source of investment-grade yield, especially if rate hikes pause. Key risks include rising interest rates pressuring bond prices and potential credit spread widening if economic conditions deteriorate.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →
